Exclusive Summary

• The originator patent has long expired, making this a mature, high-volume chronic disease product ideal for quickly capturing emerging market share and government procurement tenders via distribution agreements.
• With a massive global patient base for hyperlipidemia and hypertriglyceridemia (affecting >25% of adults globally), it acts as a highly demanded foundational therapy for preventing acute pancreatitis in severe cases.
• Backed by China's mature API and FDF vertically integrated supply chain, it offers significant cost advantages, directly maximizing overseas distributors' win rates in highly price-sensitive tender markets.
• Supported by ready-to-file CTD dossiers and strict GMP compliance, it facilitates highly efficient, cost-effective registration and commercialization for partners in LATAM, SEA, and MENA regions.